Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview

Palisade Bio

07/08/2026 22:15

Palisade Bio Inc PALI.OQ PALI.O is expected to  show no change in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Palisade Bio Inc is for a loss of 5 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Palisade Bio Inc is $8.00, about 282.8% above its last closing price of $2.09
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.04
-0.04
-0.05
Missed
-16.7
Dec. 31 2026
-0.04
-0.08
-0.08
Met
1.6
Sep. 30 2025
-0.22
-0.27
-0.38
Missed
-38.5​
Jun. 30 2025
-0.56
-0.56
-0.58
Missed
-3.4
​​Mar. 31 2025
-0.68
-0.70
-0.47
Beat
32.9
Dec. 31 2024
-0.81
-1.99
-1.55
Beat
22.1​
Sep. 30 2024
-3.37
-3.35
-2.32
Beat
30.8
Jun. 30 2024
-2.92
-2.93
-3.32
Missed
-13.3
This summary was machine generated August 7 at 21:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)